People diagnosed with a life-threatening heart condition have been given fresh hope thanks to a ground-breaking new drug, researchers say.
A study shows that patients with transthryretin amyloid cardiomyopathy, (ATTR-CM), now the most commonly diagnosed form of amyloidosis (protein build up in the body), benefited significantly when they took the drug Acoramidis.
